The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Ampyra (dalfampridine-ER) was approved by the FDA (2010) for improving walking speed in persons with multiple sclerosis. This project seeks to determine if there are other benefits to taking dalfampridine besides an increase in walking speed. This is strictly an observational study and research staff will not be involved in any decisions to stop or start taking the medication.

Condition or disease

Multiple Sclerosis

Detailed Description:

Subjects will be evaluated before starting medication, throughout a 14week period after starting D-ER as well as at 12 and 18months following the start date of medication regardless of if they stayed on medication or not.

Anyone prescribed D-ER per usual clinical care was recruited into this observational study. All those willing to participate were consented and observed pre-drug and for a 14week period with two follow-up visits scheduled at 12 and 18months.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Sampling Method:

Non-Probability Sample

Study Population

Persons with MS who have been prescribed ampyra at the Mandell Center for Multiple Sclerosis.

Criteria

Inclusion Criteria:

Confirmed clinical diagnosis of MS by McDonald criteria

Prescribed ampyra (dalfampridine) as part of usual care, but have not yet started taking the medication before baseline visit

Receive MS care at the Mandell MS center

Cognitively able to understand directions and complete protocol (score of 22 or greater on the MMSE)

18 years of age or older

Exclusion Criteria:

Already began to take drug prior to baseline research visit

Not planning to continue care at Mandell Center for at least 14 weeks after initiation of therapy